Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.
Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 (177Lu) and Actinium-255 (255Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which have limited treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.
Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen, which has remained a shareholder of the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, the United Kingdom, and the United States.
Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.
Company Details
- Employees
- 36
- Founded
- -
- Address
- Robert-Rössle-Straße. 10, Building 79,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Berlin
Ariceum Therapeutics Questions
Ariceum Therapeutics's website is http://www.ariceum-therapeutics.com
Ariceum Therapeutics's LinkedIn profile is https://de.linkedin.com/company/ariceum-therapeutics
Ariceum Therapeutics has
36 employees.
View email and phone details for 36
employees at Ariceum Therapeutics.
Ariceum Therapeutics's industry is
Biotechnology Research
Ariceum Therapeutics's top competitors are
Nucleus Radiopharma,
Full-Life Technologies,
Mariana Oncology,
Ratio Therapeutics,
Artbio,
Radiopharm Theranostics,
Theragnostics,
Orano Med,
Telix Pharmaceuticals Limited,
Itm Isotope Technologies Munich Se.
Ariceum Therapeutics's categories are Biotechnology Research
Ariceum Therapeutics's founding year is 2021
